1.
Br J Haematol
; 201(6): 1033-1046, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37170397
RESUMO
CD30 is a transmembrane protein from the tumour necrosis factor receptor superfamily. It is expressed on a small subset of activated T and B lymphocytes, and various lymphoid neoplasms. CD30 is a particularly interesting treatment target because its levels are high in tumours but low in healthy tissues. Several therapeutic strategies targeting CD30 have been developed, including monoclonal antibodies, conjugated antibodies (combination of brentuximab vedotin with chemotherapy or immunotherapy), bispecific antibodies and cell and gene therapies, such as anti-CD30 CAR-T cells in particular. We briefly review the biology of CD30 which makes it a good therapeutic target, and we describe all of the anti-CD30 therapies that have emerged to date.
Assuntos
Neoplasias Hematológicas , Imunoconjugados , Adulto , Humanos , Anticorpos Monoclonais/uso terapêutico , Brentuximab Vedotin , Neoplasias Hematológicas/tratamento farmacológico , Imunoconjugados/uso terapêutico , Antígeno Ki-1
2.
Ann Oncol
; 32(10): 1294-1295, 2021 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34171494
Assuntos
COVID-19 , Neoplasias , Vacinas , Vacina BNT162 , Vacinas contra COVID-19 , Humanos , Neoplasias/tratamento farmacológico , Soroconversão
3.
Ann Oncol
; 32(8): 1051-1053, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33932501
4.
Ann Oncol
; 29(4): 1065-1066, 2018 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29346600